TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04514809

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: human milk analized
Description: After birth (24-72 hours) 15 ml, and end of the first month of birth 30 ml of milk from the mother will be milked in the appropriate way and put into the sterile milk collection container. The milk taken into the milk transport container will be delivered to the Nutrition Lab for analysis (moisture, protein, fat, lactose) by the researcher who arrives at the TUBITAK Mam Research Center as fresh within 3 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: human milk analized
Description: After birth (24-72 hours) 15 ml, and end of the first month of birth 30 ml of milk from the mother will be milked in the appropriate way and put into the sterile milk collection container. The milk taken into the milk transport container will be delivered to the Nutrition Lab for analysis (moisture, protein, fat, lactose) by the researcher who arrives at the TUBITAK Mam Research Center as fresh within 3 hours
Study: NCT02426671

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MuteButton sensory stimulation device
Description: Participants are asked to use the MuteButton daily for 30-40 minutes. They receive 'pink noise' through headphones and transcutaneous stimulation on the tongue using a 'lollipop' sensor that sits on the anterior section (tip) of the tongue.
Study: NCT05747846

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carpal tunnel release, WALANT technique
Description: Patients will receive 20 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel. Patients will go under open carpal tunnel release without a tourniquet.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carpal tunnel release using a tourniquet
Description: Patients will receive 20 ml of 1% lidocaine with 1:100,000 epinephrine (buffered 10:1 with 8.4% sodium bicarbonate). Thirty minutes before carpal tunnel release surgery, 10 mL will be injected subcutaneously, and 10 mL will be injected into the carpal tunnel. Patients will go under open carpal tunnel release using a hemostatic cuff. The hemostatic cuff will be insufflated at the level of the arm at a pressure of 100 mmHg higher than the patient's systolic pressure. The cuff will be removed once wound closure is complete.
Study: NCT03889717

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D
Description: vitamin d drops will be given daily to the 2 groups of neonates ( 1st group will be given 400 iu /day and 2nd group will be given 1000 iu per day ) when they reach 100 cc per kg enteral feeding .. until they reach 40 weeks gestational age

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: vitamin d drops will be given daily to the 2 groups of neonates ( 1st group will be given 400 iu /day and 2nd group will be given 1000 iu per day ) when they reach 100 cc per kg enteral feeding .. until they reach 40 weeks gestational age
Study: NCT02671669

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Discharge packet of Heart Healthy instructions, with self-report health status, quality of life and psychosocial questionnaires, as well as other educational handouts, exit interview to review exercise progress, receive referrals to additional medical services they might need after discharge from the program, with physician.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Movn application (MVN)
Description: Intervention participants will receive the same discharge packet as the UC group along with their exit interview and will receive the following:~* Participant individualized Heart Healthy instructions for post-cardiac rehabilitation will be integrated into the MVN application including daily medication reminders, physical activity prompts, educational materials, and patient-reported outcome assessment of behavior and psychosocial status.~* Text messages will be used on an ad hoc basis to provide positive feedback to the participant; two-way messaging between the participant and the research coordinator will be available to provide opportunities to answer specific questions.
Study: NCT00726531

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Otago Exercise Programme
Description: Home based exercise programme (OEP) This exercise programme consists of a 30 minute programme of leg muscle strengthening and balance retraining exercises progressing in difficulty to be performed at home at least three times per week, and a walking plan to be undertaken at least two times per week for 24 weeks. . Trained peer mentors will contact and visit the patients at their home to start the exercise programme with them and will follow-up with up to three more home visits / exercise sessions as the participants require

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fame
Description: Community based exercise programme (FaME) FaME includes and extends the OEP. It will comprise one hour PSI delivered group exercise class in a local community centre for a maximum of 15 participants, and two 30 minute home exercise sessions (based on the extended OEP) per week for 24 weeks. Participants will also be advised to walk at least twice per week for up to 30 minutes at a moderate pace.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Treatment As Usual
Description: Treatment as usual by the general practitioner
Study: NCT00734305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-121
Description: Dose escalation Frequency - once weekly
Study: NCT01977105

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Grow Together peer group
Description: Participants in this intervention will:~* Participate in Facebook group of 6-10 peers for about 8 weeks, led by a professional group mentor.~* Complete an intervention video activity approximately weekly:~  * 1. View educational videos addressing topics related to healthy infant growth~ * 2. Create photos/videos modeling healthy behaviors and post them to the group~ * 3. Provide and receive feedback on posts~ * 4. Be encouraged to share information with key caregivers of their child~* Attend group party soon after enrollment, to meet peers and group leader in person.~* Receive text message reminders, 1) to schedule recommended primary care visits for their infant, and 2) to attend appointments scheduled in CHOP Care Network.~* Have basic program information provided to pediatrician to enhance conversation during office visits.
Study: NCT01611883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: 10 mg oral dose once daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match ezetimibe orally once daily for 24 weeks.
Study: NCT03120780

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl 20 mcg
Description: 20 mcg fentanyl in 10 mL 0.125% bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl 100 mcg
Description: 100 mcg fentanyl in 10 mL 0.125% bupivacaine
Study: NCT02727478

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HiBalance training program
Description: The program consists of physiotherapist led highly challenging balance exercises, which are adapted and progressed on both a group and individual basis throughout the training period.
Study: NCT02731001

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photon therapy
Study: NCT01076400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adavosertib
Description: Adavosertib capsules are administered in sequentially rising dose levels twice daily for a total of nine doses on Days 1-5 of a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adavosertib
Description: Adavosertib capsules are administered in sequentially rising dose levels twice daily for a total of nine doses on Days 1-5 of a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan is administered at a dosage of 0.75 mg/m\^2 by intravenous (IV) infusion over 30 minutes on Days 1-3.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topotecan
Description: Topotecan is administered at a dosage of 0.75 mg/m\^2 by intravenous (IV) infusion over 30 minutes on Days 1-3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan is administered at a dosage of 0.75 mg/m\^2 by intravenous (IV) infusion over 30 minutes on Days 1-3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is administered at a dosage of 50 mg/m\^2 by IV infusion over 30 minutes on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin is administered at a dosage of 50 mg/m\^2 by IV infusion over 30 minutes on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is administered at a dosage of 50 mg/m\^2 by IV infusion over 30 minutes on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to adavosertib
Description: Placebo to adavosertib capsules are administered in sequentially rising dose levels twice daily for a total of nine doses on Days 1-5 of a 21-day cycle.
Study: NCT03007316

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VIP graft
Description: surgical soft tissue grafting concomitant to implant placement
Study: NCT02239510

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Senna
Description: 1 capsule (50 mg) Senna daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linzess
Description: 1 capsule (145 mcg) of Linzess once daily for 12 weeks
Study: NCT05699863

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Lifestyle intervention in the form of individualised dietitian consultation with the overall goal of weight loss.~Intervention includes one initial consultation with a dietician of 1 hour and 15 minutes where participants receive a personalised diet-plan customised to the participants everyday life. After the initial consultation, the participants attend 10 follow-ups of about 25 minutes that are spread out over 4-5 months.
Study: NCT03949699

Intervention type: OTHER
Group type: OTHER
Intervention: Resistance training
Description: Participants will engage in strengthening exercises using a cable tower while seated. These movements will include trunk flexion and extension, diagonal trunk rotation, and lateral trunk flexion. The goal for resistance training frequency (Weeks 1-8) will be three times per week, lasting about 30-45 minutes per session including warm-up/cool-down, for a duration of eight weeks. Resistance intensity of each exercise will also be determined based on the initial maximal strength performing that exercise: Weeks 1-4 will be 50-60% of the baseline calculated 1 repetition maximum (RM) values; Weeks 5-8 will use resistive loads equivalent to 50-60% of Week 4 1RM calculations
Study: NCT00401791

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: * Interval Exercise Training: Each interval training session will start with 10 minutes of warm up and will end with 10 minutes of cool down period at 40% VO2 peak. Training duration, intensity and number of exercise bout will increase with the progression of training period~* Aerobic training: Each endurance training session will start with 5 minutes of warm up and will end with 5 minutes of cool down at 40% VO2 peak. Subjects will exercise at 70% VO2 peak for 45 minutes on day 3 and 5, for 55 minutes on day 8 and 10, and for 35 minutes on day 14 using a bicycle ergometer.
Study: NCT01846988

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: crossover treatment (REMstar Auto A-Flex)
Description: All subjects will use same device with 4 week crossover of settings of APAP and CPAP
Study: NCT03391843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI+Cetuximab regimen
Description: FOLFOXIRI+Cetuximab Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h +Cetuximab 500mg/m²,all on day 1 of each 2 weeks cycle
Study: NCT02507089

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored sleep health education materials.
Description: Tailored sleep health materials.
Study: NCT01846988

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: crossover treatment (REMstar Auto A-Flex)
Description: All subjects will use same device with 4 week crossover of settings of APAP and CPAP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: crossover treatment (REMstar Auto A-Flex)
Description: All subjects will use same device with 4 week crossover of settings of APAP and CPAP
Study: NCT03530345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neridronic acid 100 mg
Description: 100 mg neridronic acid supplied in glass vials in 8 mL of excipients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Glass vials with matching placebo.
Study: NCT02931994

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Knotted floss technique
Description: The subjects use the knotted floss technique. In this modification of conventional flossing technique, a knot is tied in the floss at any distance in the middle third of the floss length. The floss is inserted past the interdental contact point by the conventional finger flossing technique in the non-knotted area and then during the 'to and fro movement' on the tooth surface cervical to contact point, the knotted area is engaged through the embrasure (Gomes et al 2016)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Knotted floss technique
Description: The subjects use the knotted floss technique. In this modification of conventional flossing technique, a knot is tied in the floss at any distance in the middle third of the floss length. The floss is inserted past the interdental contact point by the conventional finger flossing technique in the non-knotted area and then during the 'to and fro movement' on the tooth surface cervical to contact point, the knotted area is engaged through the embrasure (Gomes et al 2016)
Study: NCT00442026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel at the dose of 30mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine at the dose of 900mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine at the dose of 1200mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
Study: NCT01436045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Description: Single treatment, 20 IU/Intranasal (.1ml/10 units Intranasally in each nostril)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Single treatment,(saline) 20 IU/Intranasal (.1ml/10units intranasally in each nostril)
Study: NCT01914302

Intervention type: DEVICE
Intervention: Delica Lancing Device
Description: Characterize Blood Volume and Pain under normal use circumstances

Intervention type: DEVICE
Intervention: Flash Lancing Device
Description: Characterize Blood Volume and Pain under normal use circumstances
Study: NCT02507089

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Generic sleep health education materials.
Study: NCT01031823

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-Media Social Skills Training Program
Description: All individuals will participate in a twelve week social skills training program designed to enhance the social skills of adolescents with Asperger's Disorder or high-functioning autism. The intervention is comprised of both group therapy and peer generalization.
Study: NCT03778736

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cumulase denudation
Description: Testing the effect of cumulase for women with poor oocyte yield due to poor ovarian reserve
Study: NCT04488731

Intervention type: BEHAVIORAL
Intervention: Normal BMI and moderate coffee consumption
Description: Normal BMI and moderate coffee consumption
Study: NCT02374931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 16 Alpha-Fluoroestradiol
Description: Undergo 18F-FES PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo 18F-FES PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo 18F-FES PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01635686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP422 25mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ENBREL 25MG PFS INJ.
Study: NCT02034994

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eating behavior and physical activity change
Description: A combination of two prevention school based programs will be addressed to schoolchildren over one year. Primary prevention will be developed monthly in order to reduce cookies and sugar sweetened beverages consumption, reduction of sedentary activities, increase meal consumption frequency and quality etc, in all children from 6th and 7th grades. Overweight and obese children will be invited to participate on a secondary prevention program in which daily physical activity classes will be performed by physical education teachers in school facilities.
Study: NCT02955810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT01954784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Description: Undergo nonmyeloablative allogeneic hematopoietic SCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02905318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: 125 mg orally on days 1-21 each 28 day cycle
Study: NCT03772184

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical inversion
Description: inverting the cervical lip after delivery
Study: NCT04106856

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan Potassium
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04072744

Intervention type: DEVICE
Intervention: Heartfelt measurements
Description: The measurements taken using the Heartfelt device do not require contact with the participant. For the measurements to take place, the participant will simply walk in the field of view of the device. As the device(s) will have been installed at a location allowing the best view of where the participant goes in an out of bed, the participant is not expected to change anything to their routine.~The device can also take measurements in the dark, so if the participant walks in front of the device in the dark, this information will also be captured.~The Heartfelt device is a CE (European Conformity) marked product. Neither the participant, or the medical team will be able to see the data collected by the Heartfelt device during the study. They will be blinded to the data until each participant has completed the study. At that point they can choose to review the data from participant individually or wait until all the data from all participants is available.

Intervention type: DEVICE
Intervention: Connected weighing scales
Description: The participant will be instructed to use those scales for the period of the study, as often as directed by their healthcare professional. The weighing scales display weight so that the participants can record the weight in their own heart failure records.~The participant will be able to see the weight readings on the weighing scales during the study.~The scales will communicate with the Personal Computer (PC) contained in the Heartfelt device and the data will be sent to the Heartfelt server through an encrypted link.
Study: NCT01162135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: The participants will take study drug digoxin, which is approved by FDA for the treatment of CHF, 125 or 250 mcg orally daily, titrated to the level of 0.8 - 2 ng/ml for total of 6 cycles (4 weeks/cycle). The lower dose of digoxin (such as 125 mcg/day) will be chosen if serum level reaches 0.8 ng/ml already. Patients may continue another 6 cycles if evident of clinical benefit.~It is possible that some patients may need to receive 500 mcg per day to reach this targeted drug level. No further titration will be allowed beyond this FDA approved digoxin dose.
Study: NCT04794452

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Battery operated toothbrush
Description: Device on plaque removal efficacy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual toothbrush
Description: Device on plaque removal efficacy
Study: NCT02420665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proflavine
Description: 0.01% Proflavine applied topically to the cervix after colposcopy and HRME cervical images obtained.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HRME Imaging
Description: HRME images obtained from one visually normal cervical site, and from up to 3 visually abnormal lesions based on exam and/or colposcopic findings.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Call
Description: Study staff follow up with participant by phone one month after procedure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colposcopy
Description: Colposcopy performed after visual inspection of cervix.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetic Acid
Description: 3 - 5% added to cervix before visual inspection.